Leukemia trial hopes to boost chemo with immune drug

NCT ID NCT04802161

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding the drug pomalidomide to standard chemotherapy (daunorubicin and cytarabine liposome) helps people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) linked to prior bone marrow disorders. About 50 participants will receive either the chemo alone or chemo plus pomalidomide. The main goal is to see if the combination leads to more complete remissions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pomalidomide combined with liposomal daunorubicin and cytarabine
What this could lead to: If successful, this could lead to a more effective treatment for a hard-to-treat type of acute myeloid leukemia, potentially improving remission rates.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 50 participants. Adding pomalidomide may increase side effects without improving outcomes, and results may not apply to all AML patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia with multilineage dysplasia chronic myelomonocytic leukemia myelodysplastic syndrome Myelodysplastic Syndromes Myeloproliferative Disorders myeloproliferative neoplasm therapy related acute myeloid leukemia and myelodysplastic syndrome therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY ACUTE MYELOID LEUKEMIA WITH MULTILINEAGE DYSPLASIA CHRONIC MYELOMONOCYTIC LEUKEMIA MYELODYSPLASTIC SYNDROME MYELOPROLIFERATIVE NEOPLASM

Contacts and locations

Locations

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
NYP/Weill Cornell Medical Center

New York, New York, 10065, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219, United States
University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66160, United States
University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205, United States
University of Virginia Cancer Center

Charlottesville, Virginia, 22908, United States
Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.